Ignite Creation Date:
2024-05-06 @ 7:11 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05924880
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-25
First Post:
2023-06-01
Brief Title:
A Phase 3b Open-label Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers BTC
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-07-21
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-06-01
First Submit QC Date:
June 20 2023
Study First Post Date:
2023-06-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-24
Last Update Post Date:
2024-06-25
Last Update Post Date Type:
ACTUAL